| Years |
Change in group size resulting from a general screening program |
Total diabetes-related costs under actual practice |
Total diabetes-related costs with a screening program |
Gross benefit |
| Group 1 |
Group 2 |
Group 3 |
Group 4 |
| 2013 |
0 |
0 |
0 |
0 |
18,700,000,000 € |
18,700,000,000 € |
- |
| 2014 |
2,916 |
3,188 |
-3,621 |
-2,483 |
19,666,666,667 € |
19,611,005,509 € |
55,661,157 € |
| 2015 |
5,535 |
6,120 |
-6,587 |
-5,007 |
20,633,33,333 € |
20,521,702,557 € |
111,630,065 € |
| 2016 |
7,905 |
8,826 |
-8,997 |
-7,552 |
21,600,000,000 € |
21,432,369,935 € |
167,630,065 € |
| 2017 |
10,061 |
11,330 |
-10,933 |
-10,103 |
22,566,666,667 € |
22,343,227,837 € |
223,438,830 € |
| 2018 |
12,035 |
13,655 |
-12,466 |
-12,647 |
23,544,333,333 € |
23,254,448,529 € |
278,884,805 € |
| Cumulated gross benefit |
837,245,633 € |
|
